R&D Systems Inc. Tocris Bioscience Boston Biochem

API-2

Cat. No. 2151

API-2 C13H16N6O4 [35943-35-2]

Price and Availability

For API-2 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Names: Triciribine, NSC 154020, TCN

Chemical Name: 1,5-Dihydro-5-methyl-1-β-D-ribofuran­osyl-1,4,5,6,8-pentaazaacenaphthylen-3-amine

Biological Activity

Selective inhibitor of Akt (protein kinase B) signaling; displays minimal inhibition of PKC, PKA, SGK and p38 pathways. Inhibits phosphorylation and activation of downstream targets of Akt including Bad, GSK-3β and AFX. Induces apoptosis and growth arrest in vitro, preferentially in human cancer cells with elevated levels of Akt. Potently and selectively inhibits growth of Akt-overexpressing tumors in mice. Inhibits DNA synthesis and displays antiviral activity against HIV-1 and -2.

Technical Data

M.Wt:
320.31
Formula:
C13H16N6O4
Solubility:
Soluble to 100 mM in 1eq. HCl and to 100 mM in DMSO
Purity:
>99 %
Storage:
Store at RT
CAS No:
35943-35-2

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch
Select another batch:
Safety Data Sheet: View Safety Data Sheet

References

Wotring et al (1990) Dual mechanisms of inhibition of DNA synthesis by triciribine. Cancer Res. 50 4891. PMID: 2379153.

Ptak et al (1998) Phosphorylation of triciribine is necessary for activity against HIV type 1. AIDS Res.Hum.Retroviruses. 14 1315. PMID: 9788672.

Yang et al (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumour activity in cancer cells overexpressing Akt. Cancer Res. 64 4394. PMID: 15231645.

If you know of a relevant citation for this product please let us know.

Keywords: API-2, supplier, Selective, inhibitors, Akt, PKB, signaling, Antitumor, antiviral, Protein, Kinase, B, NSC154020

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Guide

Request your free copy

Cancer Research Guide

Highlights over 350 products for cancer research. Request a copy or view PDF today.

divider line

Kinases Product Listing

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Some of the most potent
kinase inhibitors all on one plate

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

Angiogenesis Poster

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

divider line

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

Schizophrenia Poster

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.

divider line

Akt Pathway

Akt Pathway

Akt signaling is involved in fundamental cellular processes such as protein synthesis, metabolism, proliferation and survival. View pathway or download PDF today.

divider line

New Product Guide

NPG

Highlights over 130 new products added in 2012. Request a copy or view PDF today.

divider line

New Products in this Area

PPY A

Potent inhibitor of Abl T315l mutant and wild-type Abl kinases

Flavopiridol hydrochloride

Cyclin-dependent kinase inhibitor

GSK2578215A

Potent, selective LRRK2 inhibitor; brain penetrant

Amlexanox

Inhibitor of TBK1 and IKKε; antiallergic agent

PF 05212384

Potent and selective dual PI 3-kinase/mTOR inhibitor

PF 03814735

Aurora kinase A and B inhibitor

PF 04691502

Dual PI 3-K/mTOR inhibitor

TNP

Inhibitor of IP6K; also inhibits IP3K

ACHP

Selective IKKα and IKKβ inhibitor

PD 0332991 isethionate

Potent, selective Cdk4/6 inhibitor; brain penetrant

CZC 24832

Selective inhibitor of PI 3-Kinase γ

LY 333531 hydrochloride

Protein kinase C inhibitor; selective for β isozymes

PF 06465469

Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK

10Z-Hymenialdisine

Pan kinase inhibitor; potently inhibits MEK-1

CP 690550 citrate

Potent JAK inhibitor

WYE 687 dihydrochloride

Potent and selective mTOR inhibitor

N,N-Dimethylsphingosine

Sphingosine kinase inhibitor

PEP 005

Protein kinase C activator

CZC 54252 hydrochloride

Potent LRRK2 inhibitor; neuroprotective

Bisindolylmaleimide II

Potent PKC inhibitor and nicotinic receptor antagonist

Sign-up for new product e-alerts
divider line

20% Discount*

Potent, selective LRRK2 inhibitor

Potent LRRK2 inhibitor now available from Tocris Bioscience

Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.

* Terms & conditions